Novartis Presents Results of Tafinlar (dabrafenib) + Mekinist (trametinib) in P-II/III (TADPOLE) Trial for BRAF V600 Low-Grade Gliomas at ASCO 2022
- The P-II/III (TADPOLE) trial evaluates Tafinlar + Mekinist vs CT in patients aged 1 to 17yrs. with BRAF V600 pLGG who required 1st systemic treatment
- The results showed ORR (47% vs 11%). In an additional analysis at a median follow-up of 18.9mos., m-PFS (20.1mos. vs 7.4mos.), tumors shrank or remained stable (86% vs 46%) and patients had a reduction in tumor size (89% vs 70%) after 1yr. of follow-up while QoL analysis favored Tafinlar + Mekinist at all time points
- The safety profile was consistent with established safety observed in prior studies, patients had fewer grades ≥3 AEs (47% vs 94%), and discontinuations due to AEs (4% vs 18%). In a separate cohort, Tafinlar + Mekinist showed an independently assessed ORR (56.1%)
Ref: Globenewswire| Image: Novartis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].